OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson
CARY, N.C., Sept. 20, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by GSK as a specialty pharmacy provider for OJJAARA™ (momelotinib). OJJAARA, approved by the U.S. Food and Drug Administration (FDA) on September 15, 2023, is an orally administered drug for the treatment of myelofibrosis (MF) in adults […]